Guillaume Bayer

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jérôme Avouac, Élodie Drumez, É. Hachulla et al. · The Lancet Rheumatology · 2021 · 291 citations · Full text

Life Sciences, Immunology, Internal Medicine +14

Etiology and Outcomes of Thrombotic Microangiopathies

Guillaume Bayer, Florent Von Tokarski, Benjamin Thoreau et al. · Clinical Journal of the American Society of Nephrology · 2019 · 159 citations · Full text

Medicine, Hematology, Pathology +12

Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study

Guillaume Bayer, Marie‐Sara Agier, Bertrand Lioger et al. · European Journal of Internal Medicine · 2019 · 53 citations · Full text

Life Sciences, Hematology, Immunology +16

White blood count, D‐dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID‐19 patients: The French multicenter CLOTVID retrospective study

J. Galland, Benjamin Thoreau, Maxime Delrue et al. · European Journal Of Haematology · 2021 · 23 citations · Full text

Medicine, Clinical Sciences, Emergency Medicine +12

D-Dimer Level and Neutrophils Count as Predictive and Prognostic Factors of Pulmonary Embolism in Severe Non-ICU COVID-19 Patients

Benjamin Thoreau, Joris Galland, Maxime Delrue et al. · Viruses · 2021 · 23 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +15